aminocaproic acid has been researched along with Pregnancy in 33 studies
Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.
Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
Excerpt | Relevance | Reference |
---|---|---|
" We sought to determine the impact of tranexamic acid and ɛ-aminocaproic acid on in vitro clotting properties in pregnancy." | 3.85 | Using antifibrinolytics in the peripartum period - concern for a hypercoagulable effect? ( Ahmadzia, HK; Grotegut, CA; Hoffman, MR; James, AH; Lockhart, EL; Murtha, AP; Swamy, GK; Thomas, SM; Welsby, IJ, 2017) |
"Administration of epsilon-aminocaproic acid, a fibrinolytic inhibitor, either orally or from an impregnated IUD, had no effect on numbers of implanted embryos, their viability, or their diameters at Day 10 of pregnancy." | 3.66 | Effects of epsilon-aminocaproic acid on fertility in the rabbit. ( Aaronson, DE; Andrade, AT; Guerra, MO; Shaw, ST, 1978) |
" On the other hand, AIHA did not affect the total length of oestrous cycle at the same dosage level used to interrupt pregnancy." | 1.29 | Antifertility effects of (+)-S-2-amino-6-iodoacetamidohexanoic acid (2-AIHA) in female rats. ( Ceballos, G; Chamorro, G; Munoz, O; Salazar, M; Salazar, S; Trujillo, J; Yanez, R, 1996) |
"Hematuria is a rather frequent complication in patients with sickling disorders." | 1.27 | Sickle-cell-induced hematuria in pregnancy. The current diagnostic and therapeutic approach. ( Fadel, HE; Hadi, HA; Kassam, SH; Milner, PF; Sanchez-Ramos, L, 1984) |
"A fibrin slide test was utilized to study cutaneous vascular plasminogen activator activity in normal rabbit, rat, monkey, and human skin and in rabbit skin following development of the local Shwartzman reaction and after substituting epsilon-aminocaproic acid for the preparatory injection of endotoxin in the local Shwartzman reaction." | 1.26 | Cutaneous vascular fibrinolytic activity in the local Shwartzman reaction. ( Bergstein, JM, 1977) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 26 (78.79) | 18.7374 |
1990's | 4 (12.12) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (9.09) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ortmann, E | 1 |
Besser, MW | 1 |
Klein, AA | 1 |
de Maat, S | 1 |
Björkqvist, J | 1 |
Suffritti, C | 1 |
Wiesenekker, CP | 1 |
Nagtegaal, W | 1 |
Koekman, A | 1 |
van Dooremalen, S | 1 |
Pasterkamp, G | 1 |
de Groot, PG | 1 |
Cicardi, M | 1 |
Renné, T | 1 |
Maas, C | 1 |
Ahmadzia, HK | 1 |
Lockhart, EL | 1 |
Thomas, SM | 1 |
Welsby, IJ | 1 |
Hoffman, MR | 1 |
James, AH | 1 |
Murtha, AP | 1 |
Swamy, GK | 1 |
Grotegut, CA | 1 |
HOEDT, HT | 1 |
ROTH, F | 1 |
ALBRECHTSEN, OK | 1 |
SKJODT, P | 1 |
SOULIER, JP | 1 |
MARZETTI, L | 3 |
MORINI, A | 1 |
SUREAU, C | 1 |
CANNON, M | 1 |
BENAGIANO, G | 1 |
LAGRUE, G | 1 |
MILLIEZ, P | 1 |
FLUTE, PT | 1 |
GRAEBER, W | 1 |
BACH, HG | 1 |
LAU, H | 1 |
SACKREUTHER, W | 1 |
SHARP, AA | 1 |
BONNAR, J | 1 |
CRAWFORD, JM | 1 |
MAKI, M | 1 |
KIKUCHI, K | 1 |
WATANABE, S | 1 |
KIKUCHI, E | 1 |
SKVARIL, F | 2 |
GRUENBERGER, D | 1 |
DREVO, M | 1 |
SLONIM, D | 1 |
STRAUSS, J | 1 |
OPPELT, HG | 1 |
BECK, L | 1 |
ADAM, E | 1 |
Niznikowska-Marks, MJ | 2 |
Oknińska, A | 2 |
Gawlik, Z | 2 |
Ostojska, J | 2 |
Grygalewicz, J | 2 |
Galczak, W | 2 |
Dubin, NH | 1 |
Cummings, DB | 1 |
Blake, DA | 1 |
King, TM | 1 |
Kassam, SH | 1 |
Hadi, HA | 1 |
Fadel, HE | 1 |
Sanchez-Ramos, L | 1 |
Milner, PF | 1 |
Linnikov, VI | 1 |
Chamorro, G | 1 |
Salazar, M | 1 |
Salazar, S | 1 |
Ceballos, G | 1 |
Trujillo, J | 1 |
Munoz, O | 1 |
Yanez, R | 1 |
Alexandrov, VA | 1 |
Bespalov, VG | 2 |
Petrov, AS | 2 |
Troyan, DN | 1 |
Bergstein, JM | 1 |
Andrade, AT | 1 |
Shaw, ST | 1 |
Guerra, MO | 1 |
Aaronson, DE | 1 |
Tucci, PL | 1 |
Biagioli, EC | 1 |
Panero, C | 1 |
Aleksandrov, VA | 1 |
Troian, DN | 1 |
Peng, TC | 1 |
Kickler, TS | 1 |
Bell, WR | 1 |
Haller, E | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Evaluation of the Minimum Concentration of Tranexamic Acid Required to Inhibit Fibrinolysis in a Population of Pregnant Women at Term.[NCT02579941] | 40 participants (Actual) | Interventional | 2015-11-30 | Completed | |||
Prophylactic Use of Topical Tranexamic Acid to Aid Surgical Haemostasis During Caesarean Sections in Parturients With Moderate to High Risk of Bleeding[NCT02492087] | Phase 3 | 84 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | ||
Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial[NCT03364491] | Phase 3 | 11,000 participants (Actual) | Interventional | 2018-03-15 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
[Key secondary outcome] Change in hemoglobin from the most recent measured before delivery to lowest measured in the 48 hours after delivery (NCT03364491)
Timeframe: from 4 weeks before delivery to 48 hours postpartum
Intervention | grams per deciliter (Mean) |
---|---|
Tranexamic Acid | -1.8 |
Placebo | -1.9 |
Mother's length of stay from delivery to discharge (NCT03364491)
Timeframe: Until hospital discharge, an average of 3 days
Intervention | days (Median) |
---|---|
Tranexamic Acid | 3 |
Placebo | 3 |
(NCT03364491)
Timeframe: within 6 weeks postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 35 |
Placebo | 32 |
This is the number of mothers who were treated with any amount of open-label TXA (not blinded study drug) or another antifibrinolytic (eg., Amicar) (NCT03364491)
Timeframe: within 7 days postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 108 |
Placebo | 109 |
This is the number of mothers who required any of the following types of surgical procedures to control bleeding: laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 233 |
Placebo | 231 |
[Key secondary outcome] This is the number of mothers who received treatments and interventions to control bleeding such as: uterotonics such as prostaglandins or methergine, but excluding oxytocin; open label TXA or other antifibrinolytics; transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets or administration of any factor concentrates; laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 892 |
Placebo | 986 |
Participants were categorized according to the amount of packed red blood cells or whole blood transfused, either as 0 to 3 units, or 4 or more units (NCT03364491)
Timeframe: within 7 days postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 20 |
Placebo | 19 |
This is the number of mothers who received during the first 7 days after delivery a transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets, or received any factor concentrates (NCT03364491)
Timeframe: within 7 days postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 29 |
Placebo | 31 |
This is the number of mothers who were treated with uterotonics such as prostaglandins or methergine, but excluding oxytocin, from delivery through 48 hours after delivery. (NCT03364491)
Timeframe: within 48 hours postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 649 |
Placebo | 732 |
[Key secondary outcome] This is the number of mothers who experienced a thromboembolic event, ischemic stroke, or myocardial infarction during the 6 weeks after delivery. (NCT03364491)
Timeframe: within 6 weeks postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 12 |
Placebo | 13 |
[Major secondary outcome] The surgeon or anesthesiologist estimated the blood loss during the delivery in milliliters, which was recorded in the anesthesia record and/or operative report (NCT03364491)
Timeframe: From skin incision to transfer from operating room, average of 1 hour
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 339 |
Placebo | 368 |
Participants were monitored from delivery until hospital discharge or 7 days after delivery (postpartum), whichever is sooner. This is the number of mothers who died for any reason, or had a blood transfusion of 1 or more units (of packed red blood cells, including whole blood or cell saver). (NCT03364491)
Timeframe: by hospital discharge or by 7 days postpartum, whichever is sooner
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 201 |
Placebo | 233 |
[Key Secondary Outcome] This is the number of mothers who experienced any of the following infectious complications in the 6 weeks after delivery: endometritis, surgical site infection, pelvic abscess (NCT03364491)
Timeframe: within 6 weeks postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 162 |
Placebo | 125 |
This is the number of mothers who experienced seizure activity, confirmed by central review, whose onset is after enrollment (NCT03364491)
Timeframe: within 6 weeks postpartum
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic Acid | 2 |
Placebo | 0 |
3 reviews available for aminocaproic acid and Pregnancy
Article | Year |
---|---|
Antifibrinolytic agents in current anaesthetic practice.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2013 |
Antifibrinolytic agents in current anaesthetic practice.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2013 |
Antifibrinolytic agents in current anaesthetic practice.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2013 |
Antifibrinolytic agents in current anaesthetic practice.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2013 |
[NEPHROLOGY IN 1964].
Topics: Acute Kidney Injury; Aminocaproates; Aminocaproic Acid; Antineoplastic Agents; Diabetes Mellitus; Di | 1964 |
PATHOLOGICAL FIBRINOLYSIS.
Topics: Aminocaproates; Aminocaproic Acid; Anticoagulants; Blood Coagulation Disorders; Blood Group Incompat | 1964 |
30 other studies available for aminocaproic acid and Pregnancy
Article | Year |
---|---|
Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations.
Topics: Aminocaproic Acid; Angioedemas, Hereditary; Antifibrinolytic Agents; Bradykinin; Complement C1 Inhib | 2016 |
Using antifibrinolytics in the peripartum period - concern for a hypercoagulable effect?
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Blood Coagulation; Case-Control Studies; Female; | 2017 |
[Case of amniotic fluid embolism treated with ypsilon-amino-caproic acid].
Topics: Aminocaproates; Aminocaproic Acid; Amniotic Fluid; Caproates; Embolism; Embolism, Amniotic Fluid; Fe | 1962 |
[Orientation on the effect of 6-aminocaproic acid in obstetrics and gynecology].
Topics: Amino Acids; Aminocaproic Acid; Blood Coagulation Disorders; Caproates; Gynecology; Obstetrics; Preg | 1962 |
Treatment of haemorrhagic diathesis by epsilon-amino-caproic acid and human fibrinogen in a case of abruptio placentae.
Topics: Abruptio Placentae; Afibrinogenemia; Amino Acids; Aminocaproic Acid; Antifibrinolytic Agents; Caproa | 1962 |
[HEMORRHAGIC SYNDROME IN LABOR].
Topics: Afibrinogenemia; Aminocaproates; Aminocaproic Acid; Aprotinin; Enzyme Inhibitors; Female; Fibrinolys | 1963 |
[THE USE OF INJECTABLE FIBRINOGEN IN SURGERY AND OBSTETRICS].
Topics: Afibrinogenemia; Aminocaproates; Aminocaproic Acid; Coagulants; Enzyme Inhibitors; Female; Fibrinoge | 1963 |
[OBSTETRICAL HEMORRHAGIC SYNDROMES. OBSERVATIONS AND CONSIDERATIONS OF A PHYSIOPATHOLOGICAL, CLINICAL AND THERAPEUTIC NATURE].
Topics: Aminocaproates; Aminocaproic Acid; Blood Coagulation Disorders; Blood Coagulation Tests; Cesarean Se | 1964 |
[FIBRINOLYSIS IN OBSTETRICS. EVOLUTION OF CONCEPTS AND THERAPEUTICS. IS ITS PREVENTION POSSIBLE?].
Topics: Afibrinogenemia; Aminocaproates; Aminocaproic Acid; Diagnosis; Female; Fibrinolysis; Humans; Obstetr | 1964 |
[TREATMENT OF HEMORRHAGIC DISEASES WITH EPSILON-AMINOCAPROIC ACID IN OBSTETRICS AND GYNECOLOGY].
Topics: Afibrinogenemia; Aminocaproates; Aminocaproic Acid; Blood Coagulation Factors; Endometritis; Erythro | 1964 |
[ON A CASE OF MASSIVE HEMATURIA OCCURRING WITHOUT APPARENT CAUSE AFTER SPONTANEOUS DELIVERY].
Topics: Aminocaproates; Aminocaproic Acid; Delivery, Obstetric; Drug Therapy; Female; Hematuria; Humans; Lab | 1964 |
HAEMORRHAGE AND FIBRINOLYSIS.
Topics: Aminocaproates; Aminocaproic Acid; Amniotic Fluid; Blood Coagulation Disorders; Blood Coagulation Te | 1964 |
[HYPOFIBRINOGENEMIC HEMORRHAGE IN PREMATURE SEPARATION OF THE PLACENTA].
Topics: Abruptio Placentae; Afibrinogenemia; Aminocaproates; Aminocaproic Acid; Blood Coagulation Tests; Blo | 1964 |
HAEMORRHAGIC DIATHESIS DUE TO ABRUPTIO PLACENTAE TREATED BY FIBRINOGEN, EPSILON-AMINOCAPROIC ACID, AND HYSTEROTOMY.
Topics: Abruptio Placentae; Aminocaproates; Aminocaproic Acid; Blood Coagulation Tests; Blood Platelets; Blo | 1965 |
A COAGULATION ANOMALY: PLASMA BEING MADE NON-CLOTTABLE BY ADDING THROMBIN, AND CLOTTABLE BY THROMBOPLASTIN-CALCIUM OR TOLUIDINE BLUE-THROMBIN.V5 BLUE-THROMBIN.
Topics: Abruptio Placentae; Afibrinogenemia; Aminocaproates; Aminocaproic Acid; Blood Coagulation Tests; Blo | 1964 |
[FATE OF ANTIBODIES DURING THE COURSE OF SPONTANEOUS CLEAVAGE OF PLACENTAL GAMMA GLOBULIN AND THE INHIBITORY EFFECT OF EPSILON-AMINOCAPROIC ACID (EACA)].
Topics: Aminocaproates; Aminocaproic Acid; Antibodies; Enterovirus C, Human; Female; gamma-Globulins; Immuno | 1964 |
[BLOOD COAGULATION DISORDERS DURING LABOR WITH SPECIAL REFERENCE TO FIBRINOLYSIS].
Topics: Aminocaproates; Aminocaproic Acid; Blood Coagulation Disorders; Drug Therapy; Female; Fibrinogen; Fi | 1965 |
THE USE OF PLACENTAL GAMMA GLOBULINS STABILIZED WITH THE EPSILON-AMINOCAPROIC ACID FOR THE PREVENTION OF MEASLES.
Topics: Aminocaproates; Aminocaproic Acid; Biomedical Research; Female; gamma-Globulins; Humans; Measles; Ph | 1965 |
[Studies on the effect of oral contraceptives and epsilon-aminocaproic acid on pregnant rats and their fetuses with particular attention to the coagulation tests].
Topics: Afibrinogenemia; Aminocaproates; Aminocaproic Acid; Animals; Blood Coagulation Tests; Chlormadinone | 1980 |
[Effect of oral contraceptives and epsilon-aminocaproic acid on pregnant female rats and their fetuses. Histopathologic study].
Topics: Abnormalities, Drug-Induced; Aminocaproates; Aminocaproic Acid; Animals; Chlormadinone Acetate; Cont | 1981 |
Effect of epsilon amino caproic acid, a fibrinolytic inhibitor, on implantation and fetal viability in the rat.
Topics: Aminocaproates; Aminocaproic Acid; Animals; Dose-Response Relationship, Drug; Embryo Implantation; F | 1980 |
Sickle-cell-induced hematuria in pregnancy. The current diagnostic and therapeutic approach.
Topics: Adolescent; Adult; Aminocaproates; Aminocaproic Acid; Anemia, Sickle Cell; Female; Fluid Therapy; He | 1984 |
[Experimental effect of E-aminocaproic acid on fetal hemorrhages].
Topics: Aminocaproates; Aminocaproic Acid; Animals; Drug Evaluation, Preclinical; Female; Fetal Membranes, P | 1980 |
Antifertility effects of (+)-S-2-amino-6-iodoacetamidohexanoic acid (2-AIHA) in female rats.
Topics: Abortifacient Agents; Aminocaproates; Aminocaproic Acid; Animals; Arginase; Contraceptives, Oral; Em | 1996 |
Study of post-natal effect of chemopreventive agents on ethylnitrosourea-induced transplacental carcinogenesis in rats. III. Inhibitory action of indomethacin, voltaren, theophylline and epsilon-aminocaproic acid.
Topics: Aminocaproic Acid; Animals; Anticarcinogenic Agents; Brain Neoplasms; Carcinogens; Central Nervous S | 1996 |
Cutaneous vascular fibrinolytic activity in the local Shwartzman reaction.
Topics: Aminocaproic Acid; Animals; Blood Vessels; Female; Fibrin; Fibrinolysis; Haplorhini; Humans; In Vitr | 1977 |
Effects of epsilon-aminocaproic acid on fertility in the rabbit.
Topics: Aminocaproates; Aminocaproic Acid; Animals; Embryo Implantation; Female; Fertility; Intrauterine Dev | 1978 |
Proteolytic activity of maternal serum on newborn IgD-positive lymphocytes. Study with protease inhibitors.
Topics: Aminocaproic Acid; Blood; Female; Humans; Immunoglobulin D; Infant, Newborn; Lymphocytes; Pregnancy; | 1978 |
[The inhibiting effect of epsilon-aminocaproic acid on the incidence of induced tumors of the esophagus, nervous system and kidneys].
Topics: Aminocaproic Acid; Animals; Anticarcinogenic Agents; Carcinogens; Chi-Square Distribution; Dimethyln | 1992 |
Obstetric complications in a patient with Bernard-Soulier syndrome.
Topics: Adult; Aminocaproic Acid; Bernard-Soulier Syndrome; Female; gamma-Globulins; Humans; Immunity, Mater | 1991 |